Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation

NCT01345539 is registered in ClinicalTrials.gov with Steven Burton as lead sponsor.

NCT NCT01345539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01345539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Lead sponsor
Steven Burton
Phase
Phase 2
Overall status
Terminated
Start date
June 7, 2013
Completion date
October 20, 2022
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease